Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.

J Cannon; B Fitzgerald; M Seed; Raymond Agius; A Jiwany; P Cullinan

doi:10.1093/occmed/kqu193

Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.

J Cannon, B Fitzgerald, M Seed, Raymond Agius, A Jiwany, P Cullinan

Research output: Contribution to journal › Article › peer-review

Abstract

We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.

Original language	English
Journal	Occupational medicine (Oxford, England)
Volume	65
Issue number	3
DOIs	https://doi.org/10.1093/occmed/kqu193
Publication status	Published - Apr 2015

Keywords

Asthma hazard index
respiratory sensitizer
tafenoquine.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/occmed/kqu193

Cite this

@article{9eaccdad40f9420c8e1cf842dbfa8229,

title = "Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.",

abstract = "We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.",

keywords = "Asthma hazard index, respiratory sensitizer, tafenoquine.",

author = "J Cannon and B Fitzgerald and M Seed and Raymond Agius and A Jiwany and P Cullinan",

year = "2015",

month = apr,

doi = "10.1093/occmed/kqu193",

language = "English",

volume = "65",

journal = "Occupational medicine (Oxford, England)",

issn = "1471-8405",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.

AU - Cannon, J

AU - Fitzgerald, B

AU - Seed, M

AU - Agius, Raymond

AU - Jiwany, A

AU - Cullinan, P

PY - 2015/4

Y1 - 2015/4

N2 - We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.

AB - We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.

KW - Asthma hazard index

KW - respiratory sensitizer

KW - tafenoquine.

U2 - 10.1093/occmed/kqu193

DO - 10.1093/occmed/kqu193

M3 - Article

C2 - 25663384

SN - 1471-8405

VL - 65

JO - Occupational medicine (Oxford, England)

JF - Occupational medicine (Oxford, England)

IS - 3

ER -

Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this